Researchers at the UNC School of Medicine, working with cell lines in a lab, have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and UNC scientists are developing ways to overcome such resistance.
Adriana S. Beltran, PhD, a research assistant professor in the department of pharmacology, found that the protein Engrailed 1 is overexpressed in basal-like carcinomas and designed a chain of amino acids to shut down the protein and kill basal-like tumors in the lab.
"Patients with basal-like breast cancer tend to initially respond well to chemotherapy, but it's common for patients to relapse even more aggressively," said Beltran, the first author of a paper published in the journal Oncogene. "We believe that relapse is caused by a small number of cancer cells that have stem cell properties that allow them to survive chemotherapy. In these cells we've identified the overexpression of Engrailed 1."
Beltran and her colleagues – UNC pharmacologist Lee Graves, PhD, and former UNC pharmacologist Pilar Blancafort, PhD – discovered that Engrailed 1 is not involved in the rapid proliferation of cells that cause tumor growth. Nor is Engrailed 1 present in luminal tumors – the most common form of breast cancer. The culprit protein only appears in basal-like breast cancer.
In fact, Engrailed 1 is normally confined to the brain, where it protects neurons from cell death and helps maintain their normal activity. The absence of the protein in the brain has been linked to the onset of Parkinson's disease. But there is no known function of Engrailed 1 within breast tissue.
"We think that Engrailed 1 confers protective features to breast cancer cells, similar to the features observed in long-lived neurons," Beltran said. "This may explain why these cells survive and become resistant to chemotherapy in our experiments."
The researchers found Engrailed 1 through a series of experiments designed to find genes highly expressed in basal-like cells but not in luminal breast cancers. They discovered that Engrailed 1was most highly expressed in cell lines isolated from inflammatory breast cancer. Working with the UNC Michael Hooker Proteomics Center, Beltran and colleagues also determined that Engrailed 1 was associated with the gene EPRS, which expresses an enzyme that controls messenger RNA and protein synthesis, particularly in proteins involved with inflammation.
"Inflammation is associated with cancer development," Beltran said. "It's interesting to us that Engrailed 1, alone, is able to control inflammatory responses that may promote more aggressive forms of cancer."
Why Engrailed 1 is manifested in cancerous breast tissue remains a mystery. "Nature seems to always find a way," Beltran said. "Cancer cells are part of nature; everything in nature strives to survive."
But Beltran and her colleagues might have found a way to stop Engrailed 1. After studying how Engrailed 1 binds to DNA and other proteins, the researchers created a synthetic peptide – a chain of amino acids – that can stifle the binding power of Engrailed 1. In cell lines – not in animals or patients – Beltran and colleagues used their peptide to disrupt Engrailed 1 from binding to its protein partners and DNA.
"Cancer cells need Engrailed 1 to live," Beltran said. "The peptide abolishes all interactions of Engrailed 1, and as a consequence Engrailed 1 cannot perform its functions, causing rapid cell death of the cancer cell.
"The goal now is to validate our findings in animal models."
If Engrailed 1 turns out to be as critical to basal-like metastasis as it seems from this basic research, then a drug could be developed to fight cancer relapse in some of most deadly forms of breast cancer.
Explore further: Obesity found to be major risk factor in developing basal-like breast cancer
More information: www.nature.com/onc/journal/vaop/ncurrent/full/onc2013422a.html
Medical Xpress on facebook
Related Stories
Obesity found to be major risk factor in developing basal-like breast cancer
Nov 18, 2013
Women who are obese face an increased risk of developing an aggressive sub-type of breast cancer known as 'basal-like', according to research conducted at the University of North Carolina.
Enhanced luminal breast tumor response to antiestrogen therapy
Sep 03, 2013
Breast cancer can be divided into 4 major subtypes using molecular and genetic information from the tumors. Each subtype is associated with different prognosis and should be taken into consideration when making treatment ...
Scientists identify gene that controls aggressiveness in breast cancer cells
Jul 03, 2013
In a discovery that sheds new light on the aggressiveness of certain breast cancers, Whitehead Institute researchers have identified a transcription factor, known as ZEB1, that is capable of converting non-aggressive basal-type ...
Researchers discover molecule that drives aggressive breast cancer
Jul 01, 2013
(Medical Xpress)—Recent studies by researchers at Thomas Jefferson University's Kimmel Cancer Center have shown a gene known to coordinate initial development of the eye (EYA1) is a powerful breast tumor promoter in mice. ...
Nanoparticles can overcome drug resistance in breast cancer cells
Nov 07, 2013
Nanoparticles filled with chemotherapeutic drugs can kill drug-resistant breast cancer cells, according to a study published in the scientific journal Biomaterials.
Recommended for you
Predicting nasopharyngeal carcinoma patient response to radiation therapy
3 minutes ago
Nasopharyngeal carcinoma (NPC) affects cells lining the nasopharynx. The majority of NPC cases can be cured by radiation therapy, however ~20% are resistant to radiation treatment.
EORTC Cancer in the Elderly Task Force investigates appropriate treatment for elderly patients
26 minutes ago
As we age, we experience a progressive decline in many of our bodily functions. This decline can vary greatly from individual to individual. One 75 year old might still be very active and participate in strenuous physical ...
Killer cocktail fights brain cancer
38 minutes ago
A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.
New immuno-therapy for malignant brain tumors
1 hour ago
Animal experiments show that it is relatively easy to treat cancer in the early stages. However, it is far more difficult to successfully treat advanced cancer. Treatment of brain tumors is particularly challenging because ...
Severe flu complications for cancer patients
2 hours ago
It is often noted that very young people and the elderly are most at-risk for experiencing flu-related complications, and one expert at the University of Alabama at Birmingham says people with weakened immune ...
Do aging cells become cancer?
3 hours ago
Cancers that occur in later life could be down to the way our cells age, according to a paper published in Nature Cell Biology.
User comments
© Medical Xpress 2011-2013, Phys.org network
Researchers at the UNC School of Medicine, working with cell lines in a lab, have discovered why some of the most aggressive and fatal breast cancer cells are resistant to chemotherapy, and UNC scientists are developing ways to overcome such resistance.
Adriana S. Beltran, PhD, a research assistant professor in the department of pharmacology, found that the protein Engrailed 1 is overexpressed in basal-like carcinomas and designed a chain of amino acids to shut down the protein and kill basal-like tumors in the lab.
"Patients with basal-like breast cancer tend to initially respond well to chemotherapy, but it's common for patients to relapse even more aggressively," said Beltran, the first author of a paper published in the journal Oncogene. "We believe that relapse is caused by a small number of cancer cells that have stem cell properties that allow them to survive chemotherapy. In these cells we've identified the overexpression of Engrailed 1."
Beltran and her colleagues – UNC pharmacologist Lee Graves, PhD, and former UNC pharmacologist Pilar Blancafort, PhD – discovered that Engrailed 1 is not involved in the rapid proliferation of cells that cause tumor growth. Nor is Engrailed 1 present in luminal tumors – the most common form of breast cancer. The culprit protein only appears in basal-like breast cancer.
In fact, Engrailed 1 is normally confined to the brain, where it protects neurons from cell death and helps maintain their normal activity. The absence of the protein in the brain has been linked to the onset of Parkinson's disease. But there is no known function of Engrailed 1 within breast tissue.
"We think that Engrailed 1 confers protective features to breast cancer cells, similar to the features observed in long-lived neurons," Beltran said. "This may explain why these cells survive and become resistant to chemotherapy in our experiments."
The researchers found Engrailed 1 through a series of experiments designed to find genes highly expressed in basal-like cells but not in luminal breast cancers. They discovered that Engrailed 1was most highly expressed in cell lines isolated from inflammatory breast cancer. Working with the UNC Michael Hooker Proteomics Center, Beltran and colleagues also determined that Engrailed 1 was associated with the gene EPRS, which expresses an enzyme that controls messenger RNA and protein synthesis, particularly in proteins involved with inflammation.
"Inflammation is associated with cancer development," Beltran said. "It's interesting to us that Engrailed 1, alone, is able to control inflammatory responses that may promote more aggressive forms of cancer."
Why Engrailed 1 is manifested in cancerous breast tissue remains a mystery. "Nature seems to always find a way," Beltran said. "Cancer cells are part of nature; everything in nature strives to survive."
But Beltran and her colleagues might have found a way to stop Engrailed 1. After studying how Engrailed 1 binds to DNA and other proteins, the researchers created a synthetic peptide – a chain of amino acids – that can stifle the binding power of Engrailed 1. In cell lines – not in animals or patients – Beltran and colleagues used their peptide to disrupt Engrailed 1 from binding to its protein partners and DNA.
"Cancer cells need Engrailed 1 to live," Beltran said. "The peptide abolishes all interactions of Engrailed 1, and as a consequence Engrailed 1 cannot perform its functions, causing rapid cell death of the cancer cell.
"The goal now is to validate our findings in animal models."
If Engrailed 1 turns out to be as critical to basal-like metastasis as it seems from this basic research, then a drug could be developed to fight cancer relapse in some of most deadly forms of breast cancer.
Explore further: Obesity found to be major risk factor in developing basal-like breast cancer
More information: www.nature.com/onc/journal/vaop/ncurrent/full/onc2013422a.html
Medical Xpress on facebook
Related Stories
Obesity found to be major risk factor in developing basal-like breast cancer
Nov 18, 2013
Women who are obese face an increased risk of developing an aggressive sub-type of breast cancer known as 'basal-like', according to research conducted at the University of North Carolina.
Enhanced luminal breast tumor response to antiestrogen therapy
Sep 03, 2013
Breast cancer can be divided into 4 major subtypes using molecular and genetic information from the tumors. Each subtype is associated with different prognosis and should be taken into consideration when making treatment ...
Scientists identify gene that controls aggressiveness in breast cancer cells
Jul 03, 2013
In a discovery that sheds new light on the aggressiveness of certain breast cancers, Whitehead Institute researchers have identified a transcription factor, known as ZEB1, that is capable of converting non-aggressive basal-type ...
Researchers discover molecule that drives aggressive breast cancer
Jul 01, 2013
(Medical Xpress)—Recent studies by researchers at Thomas Jefferson University's Kimmel Cancer Center have shown a gene known to coordinate initial development of the eye (EYA1) is a powerful breast tumor promoter in mice. ...
Nanoparticles can overcome drug resistance in breast cancer cells
Nov 07, 2013
Nanoparticles filled with chemotherapeutic drugs can kill drug-resistant breast cancer cells, according to a study published in the scientific journal Biomaterials.
Recommended for you
Predicting nasopharyngeal carcinoma patient response to radiation therapy
3 minutes ago
Nasopharyngeal carcinoma (NPC) affects cells lining the nasopharynx. The majority of NPC cases can be cured by radiation therapy, however ~20% are resistant to radiation treatment.
EORTC Cancer in the Elderly Task Force investigates appropriate treatment for elderly patients
26 minutes ago
As we age, we experience a progressive decline in many of our bodily functions. This decline can vary greatly from individual to individual. One 75 year old might still be very active and participate in strenuous physical ...
Killer cocktail fights brain cancer
38 minutes ago
A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.
New immuno-therapy for malignant brain tumors
1 hour ago
Animal experiments show that it is relatively easy to treat cancer in the early stages. However, it is far more difficult to successfully treat advanced cancer. Treatment of brain tumors is particularly challenging because ...
Severe flu complications for cancer patients
2 hours ago
It is often noted that very young people and the elderly are most at-risk for experiencing flu-related complications, and one expert at the University of Alabama at Birmingham says people with weakened immune ...
Do aging cells become cancer?
3 hours ago
Cancers that occur in later life could be down to the way our cells age, according to a paper published in Nature Cell Biology.
User comments
© Medical Xpress 2011-2013, Phys.org network
No comments:
Post a Comment